Biogen Inc. News
Biogen Stock Surges As New Drug Offers 'Meaningful Change' For Alzheimer's Patients
"These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently," the Alzheimer's Association said.
Stocks Nudge Higher, Powell, Bankman-Fried, Biogen, HPE in Focus -Five Things To Know
Stock futures nudge higher will Powell, jobs data in focus; Powell speech may challenge Fed's new rate hike outlook; Sam Bankman-Fried set for DealBook summit appearance after FTC collapse; Biogen shares jump after promising Alzheimer's treatment data and HPE shares surge after Q4 earnings beat, solid near-term outlook.
Biogen Stock Slumps On Report of Death in Alzheimer's Drug Trial
Science.org reported Sunday that a woman participating in the joint Biogen-Eisai Clarity AD trial of an experimental Alzheimer's treatment has died of a brain hemorrhage.
Biogen Stock Leaps, Eli Lilly Gains As Roche Alzheimer's Drug Trial Falls Short
"While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer’s dataset to the field," Roche said.
Patient Death in Alzheimer's Study May Limit Drug's Reach
Brain swelling and inflammation is a common side effect among plaque-clearing drugs. It may make some patients ineligible for treatment.
Biogen Stock Clings to Key Level After Explosive Rally
Biogen stock is up almost 40% on Wednesday but is barely holding above a key level. Let's look at the chart.
Is This the First Alzheimer's Drug to Actually Work?
Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study.
Stock Market Today: Stocks End Higher As Bank of England Intervention Clips Bond Yields
A surprise move to stem soaring bond yields by the Bank of England has U.S. stocks ending higher Wednesday.
Biogen Stock Soars On Promising Data From Late-Stage Alzheimer’s Drug Trial
“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease," said Biogen CEO Michel Vounatsos.
Stocks Resume Slump, Apple, Biogen, Elon Musk And Hurricane Ian - Five Things To Know
Stock futures resume slump on rate hike, recession concerns; Apple shares slide on report of waning iPhone demand; Biogen shares soar after positive results from Alzheimer's trial; Elon musk seeks to overturn sec rule on Twitter vetting and Hurricane Ian to slam Florida coast as category 4 storm.
Breaking News
Fed Inflation Gauge Slowed Again in October, Supporting Dovish Powell
Further slowing in the Fed's preferred inflation gauge is adding heft to Chairman Jerome Powell's signals of smaller rate hikes.
Amazon Needs to Kill Alexa, Maybe Exit Echo Devices
The online retail giant had a plan to own your living room. It didn't work because AI-powered voice assistants don't work.
General Mills Tries a New Take on Lucky Charms
The new variant may be even more magically delicious.
Elon Musk's Latest Twitter Move Looks Like an Act of Desperation
Twitter is desperate for revenue. It has a $13 billion debt burden, but hasn’t showed a profit for eight of the last 10 years.